6 results
Objective: The aim of this study is to investigate the in-vivo variability of hemostasis between patients when treated with a direct thrombin inhibitor (Dabigatran) or a direct Factor Xa (FXa) inhibitor (Rivaroxaban) by measuring thrombin generation…
To Evaluate the safety and efficacy of the sirolimus-eluting stent system BioMime Compared to the Abbott's XIENCE (V Xpedition or Prime) Everolimus-eluting stent system in the treatment of patients with up to two de novo native coronary artery…
The aim of this study is to investigate the effect of body weight on the trough concentrations of DOACs. Eliquis®, Xarelto®, Lixiana® and Pradaxa®
The primary objective is to determine whether treatment of acute intermediate-risk PE (as defined by the inclusion and exclusion criteria) with parenteral anticoagulation for at least 72 hours after diagnosis, followed by dabigatran over 6 months,…
To determine the within and between variability of pharmacokinetic (PK) profiles in patients treated with DOACs in daily practice
To measure DOAC levels just before surgery of all DOAC patients in the LUMC with elective surgery for which ceasing of DOAC treatment is required.